Search Results for “EC” – Page 256 – media

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope to identify cancerous markers. This lengthy procedure often results in patients waiting weeks or months for their results, causing treatment delays and heightened anxiety. Now, a breakthrough digital medical imaging system promises to transform cancer detection by offering instantaneous results, facilitating timely and effective treatment across all cancer types. The Photon Absorption Remote Sensing (PARS) system, an innovative, built-from-scratch technology developed by researchers at the University of Waterloo (Ontario, Canada), marks a radical departure from traditional cancer detection methods, promising diagnoses within minutes and enabling rapid surgical intervention. The system utilizes lasers to irradiate tissue samples, producing a comprehensive, high-resolution data set. This data is then processed by an artificial intelligence (AI) system that converts it into a conventional histopathology ...
- Source: drugdu
- 108
- April 29, 2024
Merck plans €300m investment at new German research centre

Merck KGaA (Merck) has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany. Set to open in 2027, the centre will be a hub for developing biopharmaceuticals, including antibodies and messenger ribonucleic acid applications. The investment is part of Merck’s broader €1.5bn commitment to the Darmstadt site by 2025. Covering an area of 18,000m², the Advanced Research Center will consolidate efforts on key life science technologies such as the production of antibodies, recombinant proteins, and viral vectors. It allows collaboration across departments of the company in an open, modern work environment. The facility will also focus on the advancement of cell culture media, pharmaceutical formulation, purification aids, and analytical chromatography. Merck said the new centre will support both European and global customers in addressing significant medical challenges. Merck CEO and executive board chair Belén Garijo said: “With ...
- Source: drugdu
- 101
- April 29, 2024
Chiatai Tianqing’s Class 1 Innovative Drug TQA3038 (siRNA) Completes Phase I Clinical Study

Recently, Chiatai Tianqing Pharmaceutical Group’s self-developed Class 1 innovative drug TQA3038 (siRNA) successfully completed Phase I clinical study. The company will start the follow-up clinical study of TQA3038 injection in patients with chronic hepatitis B in the near future. TQA3038 injection is a small interfering RNA (siRNA) drug independently developed by Chiatai Tianqing to target hepatitis B virus (HBV), with the indication of chronic hepatitis B. TQA3038, as an N-acetylgalactosamine (GalNAc)-conjugated siRNA drug, can be enriched in the liver, degrade the targeted RNA, inhibit translation of the relevant proteins, thus blocking the replication of hepatitis B virus. TQA3038 adopts a nucleic acid sequence with independent intellectual property rights and has strong in vitro and in vivo antiviral activity. The “randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic profile of TQA3038 in healthy adult subjects” initiated by the Company has been successfully completed recently. The ...
- Source: drugdu
- 133
- April 29, 2024
Nestlé India and Dr Reddy’s announces joint venture

The partnership will bring together the global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the commercial strengths of Dr. Reddy’s in India Nestlé India and Dr. Reddy’s Laboratories both together referred as “JV Partners”, today announced that they have entered into a definitive agreement to form a joint venture (“JV Company”) to bring innovative nutraceutical brands to consumers in India and other agreed territories. The partnership will bring together the global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the commercial strengths of Dr. Reddy’s in India. The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness , women’s health and child nutrition for consumers across India. The JV Company will be ...
- Source: drugdu
- 111
- April 29, 2024
Parexel partners with Palantir to accelerate clinical data delivery

Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the safety and regulatory rigor Parexel and Palantir Technologies has announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharma customers. Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity, building on the companies’ existing collaboration over the past year. Jonathan Shough, Chief Information Officer for Parexel said, “We’re thrilled to expand our collaboration with Palantir — a leader in artificial intelligence technology — as we build on our application of AI ...
- Source: drugdu
- 97
- April 29, 2024
Pharma Asia 2024

Organiser: Ecommerce Gateway Pakistan Time:20 – 22 August 2024 address：University Rd, Gulshan-e-Iqbal, Karachi- Pakistan Exhibition hall: Karachi Expo Center Product range: Medical Products exhibition area: Medical diagnostic equipment and supplies, electronic medical equipment and instruments, rescue equipment, medical reagents and equipment, etc Hospital supplies exhibition area: catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical tools, medical clothing and bedding, first aid equipment, maternal and child care equipment, disinfection equipment, etc Experimental equipment exhibition area: laboratory instruments and equipment, optical instruments and equipment, image analysis and processing system, test instruments and devices, laboratory update and transformation technology, consumables and related software, etc Medicine exhibition area: all kinds of new special medicine, proprietary Chinese medicine, Western medicine, traditional Chinese medicine health products, nutritional food, etc. Traditional medicine: Chinese medicine, herbal medicine, etc Pharmaceutical equipment exhibition area: drug production equipment and technology, drug packaging equipment, drug packaging materials, drug production, cleaning, ...
- Source: drugdu
- 156
- April 29, 2024
Exo adds FDA-cleared AI tools to handheld ultrasound system

Dive Brief Exo has made new artificial intelligence tools available on its Iris handheld ultrasound system, the company said Tuesday. The Food and Drug Administration cleared Exo’s AI tools for analyzing ultrasound images of the heart and lung last year. Exo sees the new capabilities as particularly beneficial for health systems and caregivers in rural and under-resourced settings because they simplify the collection and interpretation of images. Dive Insight Exo received a 510(k) nod for its original Iris device in 2021 and added imaging modes and indications to the clearance the following year. The clearances cover handheld portable diagnostic ultrasound systems, similar to Butterfly Network’s iQ, that enable healthcare professionals to measure body structures and fluids in adults and children. Users can view the images on smartphone screens. In 2023, Exo gained additional FDA clearances for AI products. One clearance covered software that uses machine learning to help quantify bladder ...
- Source: drugdu
- 107
- April 28, 2024
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Senator Bernie Sanders has targeted the high drug prices of Novo Nordisk’s Ozempic and Wegovy, revealing that the Senate Committee on Health, Education, Labor, and Pensions (HELP) is investigating the “outrageously high” US prices of the blockbuster diabetes and obesity drugs. In a 24 April letter addressed to Novo Nordisk CEO Lars Fruergaard Jørgensen, Sanders, who serves as the HELP Committee chair, has requested answers from the multinational pharma by 8 May. The letter said the committee is investigating future reductions of the list and net prices of both Ozempic and Wegovy, R&D spending, cost and volume of goods sold, and prices paid by government payers. Additionally, Sanders requested that Novo Nordisk explain the price discrepancy between Wegovy and Ozempic given that they are different versions of the same drug, semaglutide, sold under two brand names. Sanders had previously put forth a proposal to cap prices on federally-funded drugs in ...
- Source: drugdu
- 71
- April 28, 2024
New heart disease calculator more accurately predicts patients’ risk of CVDs

Researchers from the universities of Oxford, Nottingham and King’s College London (KCL) have shown that a new heart disease calculator can accurately predict an individual’s ten-year risk of cardiovascular diseases and identify high-risk patients. Published in Nature Medicine, the QR4 tool could save over 2,500 chronic obstructive pulmonary disease (COPD) patients a year, promoting earlier recognition of the disease and its associated cardiovascular risk. Currently the leading cause of death globally, CVDs are responsible for an estimated 17.9 million deaths each year, according to the World Health Organization. They are disorders of the heart and blood vessels. Researchers from KCL, along with the QRISK team based at the universities of Oxford and Nottingham, conducted a large-scale epidemiological study involving over 13 million UK citizens, which revealed an increased risk of severe cardiovascular events in female patients with COPD. The team identified seven new unique risk factors common to all genders ...
- Source: drugdu
- 98
- April 28, 2024
CMT Research Foundation funds study investigating treatment for CMT1X disease

The CMT Research Foundation (CMTRF) has invested in a study being led by researchers at the University of Illinois at Chicago to investigate whether a commercially available drug could potentially treat X-linked Charcot-Marie-Tooth disease (CMT1X). The study will determine whether the drug can improve symptoms in mouse models of CMT1X. Recognised as a rare, peripheral neuropathy disease that is estimated to affect more than 2.6 million people globally, Charcot-Marie-Tooth disease (CMT) is a group of inherited conditions that damage the peripheral nerves, which are found outside the main central nervous system. Currently the second most common form of CMT, CMTX1 is caused by mutations in the gene that encodes for the connexin 32 gap junction protein. Associated with inflammation, the condition is said to contribute to the damage of the protective covering of nerve cells, which leads to disease symptoms including muscle weakness, atrophy and numbness. The study, led by ...
- Source: drugdu
- 100
- April 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.